Implementing a multi arm, cohort randomized, premier, double blind placebo-controlled trial design should generate credible data to investigate the safety and non-inferiority of mRNA-encoded TZM antibodies, compared to the marketed substance, in order to aid the development of a first line medication for immunodeficient patients suffering from HER2 -neu breast and gastric cancer. Here, ERBB2 is linked to gastric cancer.